case_images: PMC10787568_01
case_images: Trial design and efficacy evaluation. (A). Trial design and timeline of the study. (B). Enhanced pelvic CT scans of patient 1 at pre-TILs infusion, 6 weeks, and 12 weeks post treatment showed a targeted lesion of 4.9cm, 3.3cm, and 3.0cm, respectively, suggesting a rapid tumor shrinkage. CT scans of patient 2 at pre-TILs infusion and 6 weeks post treatment showed a targeted lesion of 5.9cm and 5.8cm, respectively, showing a stable disease. (C). Tumor size measurements of the two patients before and after treatment. (D and E). Levels of serum biomarkers CA125 and CA153 of the two patients decreased after TILs infusion suggesting that their disease were in control.
case_images: IJWH-16-31-g0001.jpg
case_images: PMC10787568_01_IJWH-16-31-g0001.jpg
case_images: f0001
case_images: Tomography-Computed Tomography (PET-CT) results were also consistent with a cervical cancer diagnosis. The patient received 10 cycles of AK104 (10mg/kg, Q3W), bevacizumab (15mg/kg, Q3W), carboplatin (AUC=5, Q3W), and paclitaxel (175mg/m2, Q3W) between October 2021 and July 2022 (Supplemental Figure 1). She then received high doses of IL-2 for 10 days according to the clinical trial protocol (Figure 1A). Patient 1 exhibited an objective clinical response at 6 weeks post treatment, which persisted until 12 weeks post TILs infusion (Figure 1B and C) as well as a disappearance of vaginal discharge. Her metastatic lymphocyte notes near the iliac vessels were stable Patient 2 was evaluated as a stable disease (SD) at 6 weeks post treatment (Figure 1B and C). Levels of tumor monitoring biomarkers CA125 and CA153 decreased after treatment suggesting an improvement in the patients' disease condition (Figure 1D and E).